Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540244 | 0.73 | XDH (0.46) | ERN1 | |
| SCHEMBL26635161 | 0.73 | XDH (0.46) | ERN1 | |
| SCHEMBL30996252 | 0.72 | JUN (0.31) | AKR1C3AKR1C2PTGES | |
| SCHEMBL22686226 | 0.71 | KIF11 (0.35) | KCNQ3KCNQ2KCNE1KCNQ1PIK3CD | |
| SCHEMBL30540209 | 0.71 | P2RX7 (0.31) | — | |
| SCHEMBL30540236 | 0.70 | ALOX5AP (0.43) | ERN1 | |
| SCHEMBL26635226 | 0.70 | ALOX5AP (0.43) | ERN1 | |
| SCHEMBL30540206 | 0.69 | ERN1 (0.41) | ERN1 | |
| SCHEMBL16635035 | 0.69 | TRPA1 (0.34) | PTGES | |
| SCHEMBL30540254 | 0.69 | FEN1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023208151-A1 | USP INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 北京华森英诺生物科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116621778-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |